DK3506884T3 - Sammensætninger til indgivelse af medicin og anvendelser af disse - Google Patents

Sammensætninger til indgivelse af medicin og anvendelser af disse Download PDF

Info

Publication number
DK3506884T3
DK3506884T3 DK17765524.8T DK17765524T DK3506884T3 DK 3506884 T3 DK3506884 T3 DK 3506884T3 DK 17765524 T DK17765524 T DK 17765524T DK 3506884 T3 DK3506884 T3 DK 3506884T3
Authority
DK
Denmark
Prior art keywords
medicines
administration
compositions
Prior art date
Application number
DK17765524.8T
Other languages
English (en)
Inventor
Michael Solomon Goldberg
Chun Gwon Park
Original Assignee
Dana Farber Cancer Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59858787&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3506884(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dana Farber Cancer Inst Inc filed Critical Dana Farber Cancer Inst Inc
Application granted granted Critical
Publication of DK3506884T3 publication Critical patent/DK3506884T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/52—Hydrogels or hydrocolloids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Hematology (AREA)
DK17765524.8T 2016-08-30 2017-08-30 Sammensætninger til indgivelse af medicin og anvendelser af disse DK3506884T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662381456P 2016-08-30 2016-08-30
US201762486814P 2017-04-18 2017-04-18
US201762501464P 2017-05-04 2017-05-04
PCT/US2017/049424 WO2018045058A1 (en) 2016-08-30 2017-08-30 Drug delivery compositions and uses thereof

Publications (1)

Publication Number Publication Date
DK3506884T3 true DK3506884T3 (da) 2021-07-26

Family

ID=59858787

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17765524.8T DK3506884T3 (da) 2016-08-30 2017-08-30 Sammensætninger til indgivelse af medicin og anvendelser af disse

Country Status (10)

Country Link
US (5) US10435469B2 (da)
EP (2) EP3506884B1 (da)
JP (2) JP7240311B2 (da)
KR (2) KR102650076B1 (da)
CN (1) CN110121335A (da)
AU (2) AU2017321609C1 (da)
BR (1) BR112019004042A2 (da)
CA (1) CA3033542A1 (da)
DK (1) DK3506884T3 (da)
WO (1) WO2018045058A1 (da)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX349137B (es) * 2005-06-08 2017-07-13 Dana-Farber Cancer Inst Metodos y composiciones para el tratamiento de infecciones persistentes y cancer por inhibicion de la ruta de muerte celular programada (pd-1).
CN105579582A (zh) 2013-07-25 2016-05-11 埃克西奎雷股份有限公司 用于预防和治疗用途的作为免疫刺激剂的基于球形核酸的构建体
US9775844B2 (en) 2014-03-19 2017-10-03 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US11453697B1 (en) 2015-08-13 2022-09-27 Merck Sharp & Dohme Llc Cyclic di-nucleotide compounds as sting agonists
CA2998469A1 (en) 2015-09-14 2017-03-23 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same
NZ746112A (en) 2016-03-18 2023-01-27 Immune Sensor Llc Cyclic di-nucleotide compounds and methods of use
KR20230149857A (ko) 2016-07-07 2023-10-27 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 항체-애쥬번트 접합체
US11364304B2 (en) 2016-08-25 2022-06-21 Northwestern University Crosslinked micellar spherical nucleic acids
DK3506884T3 (da) 2016-08-30 2021-07-26 Dana Farber Cancer Inst Inc Sammensætninger til indgivelse af medicin og anvendelser af disse
RU2019122602A (ru) * 2016-12-20 2021-01-22 Мерк Шарп И Доум Корп. Комбинации антагонистов pd-1 и циклических динуклеотидных агонистов sting для лечения рака
US11040027B2 (en) 2017-01-17 2021-06-22 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
US11696954B2 (en) 2017-04-28 2023-07-11 Exicure Operating Company Synthesis of spherical nucleic acids using lipophilic moieties
WO2018209270A1 (en) 2017-05-11 2018-11-15 Northwestern University Adoptive cell therapy using spherical nucleic acids (snas)
WO2018232217A1 (en) 2017-06-16 2018-12-20 William Marsh Rice University Hydrogel delivery of sting immunotherapy for treatment of cancer
EP3652318A1 (en) 2017-07-11 2020-05-20 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
US20220211815A1 (en) * 2018-02-02 2022-07-07 Novartis Ag Combination therapy for the treatment of cancer
AU2019238197A1 (en) * 2018-03-20 2020-09-10 Dana-Farber Cancer Institute, Inc. Compositions and methods for cancer treatment
WO2019217547A1 (en) * 2018-05-08 2019-11-14 H. Lee Moffitt Cancer Center And Research Institute Inc. Bioengineering tertiary lymphoid structures using chitosan-based hydrogels
WO2019226516A1 (en) 2018-05-24 2019-11-28 Celanese EVA Performance Polymers Corporation Implantable device for sustained release of a macromolecular drug compound
CN111989068A (zh) 2018-05-24 2020-11-24 塞拉尼斯伊娃高性能聚合物公司 用于持续释放大分子药物化合物的可植入器件
SG11202100023XA (en) 2018-07-11 2021-01-28 Actym Therapeutics Inc Engineered immunostimulatory bacterial strains and uses thereof
WO2020023361A1 (en) * 2018-07-23 2020-01-30 H. Lee Moffitt Cancer Center And Research Institute Inc. Enhancing anti-tumor response in melanoma cells with defective sting signaling
US20220072166A1 (en) * 2018-07-25 2022-03-10 Advanced Accelerator Applications S.A. Method of treatment of neuroendocrine tumors
US10596276B2 (en) 2018-07-25 2020-03-24 Advanced Accelerator Applications (Italy) S.R.L. Stable, concentrated radionuclide complex solutions
EP3844276A2 (en) 2018-08-28 2021-07-07 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
WO2020069488A1 (en) * 2018-09-28 2020-04-02 North Carolina State University Compositions and methods for drug delivery
TW202028212A (zh) 2018-10-11 2020-08-01 日商小野藥品工業股份有限公司 Ｓｔｉｎｇ促效化合物
US20210393758A1 (en) * 2018-10-26 2021-12-23 Istituto Oncologico Veneto Iov-Irccs Hyaluronic acid as a natural adjuvant for protein and peptide-based vaccines
US11274150B2 (en) 2018-11-16 2022-03-15 Bristol-Myers Squibb Company Anti-human natural killer cell inhibitory receptor group 2A protein (NKG2A) antibodies
CA3119341A1 (en) * 2018-11-16 2020-05-22 Neoimmunetech, Inc. Method of treating a tumor with a combination of il-7 protein and an immune checkpoint inhibitor
RU2742580C2 (ru) * 2018-12-26 2021-02-08 федеральное государственное бюджетное учреждение «Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи» Министерства здравоохранения Российской Федерации Фармацевтическая композиция на основе PLGA для индукции эффективного мукозального иммунного ответа
WO2020141225A1 (en) * 2019-01-04 2020-07-09 Ascendis Pharma A/S Minimization of systemic inflammation
EP3906018A1 (en) * 2019-01-04 2021-11-10 Ascendis Pharma Oncology Division A/S Induction of sustained local inflammation
CN109701092B (zh) * 2019-01-29 2021-11-09 西安交通大学医学院第一附属医院 一种可降解(p3/4hb-pcl)-pu医用胆道支架材料及制备方法
CN116063520A (zh) 2019-01-30 2023-05-05 真和制药有限公司 抗gal3抗体及其用途
WO2020180904A1 (en) * 2019-03-04 2020-09-10 North Carolina State University Drug delivery for combination of epigenetic modulation and immune checkpoint blockade
WO2020190725A1 (en) 2019-03-15 2020-09-24 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
TW202102545A (zh) * 2019-04-02 2021-01-16 美商麥迪紐有限責任公司 用於治療腫瘤之抗cd73、抗pd-l1抗體及化學治療
WO2020206128A1 (en) * 2019-04-02 2020-10-08 The Johns Hopkins University Artificial t cell stimulating matrix for immunotherapy
CN111793134A (zh) * 2019-04-08 2020-10-20 华中科技大学 一种用于癌症治疗中的药物、肿瘤疫苗及抑制剂
EP3962524A4 (en) * 2019-05-02 2023-06-14 Surge Therapeutics, Inc. CANCER TREATMENT
US11787833B2 (en) 2019-05-09 2023-10-17 Aligos Therapeutics, Inc. Modified cyclic dinucleoside compounds as sting modulators
WO2020232247A1 (en) 2019-05-14 2020-11-19 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
EP3986449A4 (en) * 2019-06-21 2023-08-02 North Carolina State University IN SITU RECRUITMENT, REPROGRAMMING AND RELEASE OF T LYMPHOCYTES CARRIER OF CHIMERIC ANTIGENIC RECEPTORS (CAR-T)
WO2020259667A1 (zh) * 2019-06-28 2020-12-30 江苏恒瑞医药股份有限公司 Tlr激动剂与抗ox40抗体或其抗原结合片段联合在制备治疗肿瘤的药物中的用途
CN114786729B (zh) 2019-07-19 2023-12-19 免疫传感器治疗股份有限公司 抗体-sting激动剂缀合物及其在免疫疗法中的用途
WO2021042778A1 (zh) * 2019-09-03 2021-03-11 苏州百迈生物医药有限公司 一种治疗肿瘤的温敏型凝胶药物组合物
EP3791858A1 (en) * 2019-09-13 2021-03-17 UPM-Kymmene Corporation Injectable pharmaceutical formulation
EP3791864A1 (en) 2019-09-13 2021-03-17 UPM-Kymmene Corporation Method for preparing pharmaceutical composition and pharmaceutical composition
WO2021055660A1 (en) * 2019-09-18 2021-03-25 The Regents Of The University Of California Protein producing nanoliposomes and uses thereof
CN113730570A (zh) * 2019-09-26 2021-12-03 苏州百迈生物医药有限公司 一种化疗免疫组合药物及其应用
CN110680951B (zh) * 2019-10-31 2021-01-19 西安交通大学 一种腺嘌呤增强可降解软组织粘合剂及其制备和使用方法
US20230131219A1 (en) * 2019-11-08 2023-04-27 The University Of North Carolina At Chapel Hill Use of agonists to augment car t function in solid tumors
CA3176713A1 (en) * 2019-12-09 2021-06-17 Cedars-Sinai Medical Center Use of fgfr inhibitors for treatment of idiopathic short stature
US20230218771A1 (en) * 2020-02-04 2023-07-13 The Johns Hopkins University Self-assembling prodrugs as immune boosters for cancer immunotherapy
WO2021174021A1 (en) * 2020-02-27 2021-09-02 Fred Hutchinson Cancer Research Center Tunable extended release hydrogels
WO2021187813A1 (ko) * 2020-03-16 2021-09-23 주식회사 스칼라팍스트롯 변형가능한 하이드로젤 입자 및 이를 포함하는 암 치료용 약학 조성물
US20230149540A1 (en) * 2020-04-06 2023-05-18 The Board Of Trustees Of The Leland Stanford Junior University Vaccine platform for the induction of systemic immune responses
EP4134098A4 (en) * 2020-04-10 2024-05-15 ONO Pharmaceutical Co., Ltd. CANCER THERAPY METHODS
US12006366B2 (en) 2020-06-11 2024-06-11 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
CN111920946B (zh) * 2020-08-07 2021-05-28 合肥诺为尔基因科技服务有限公司 环二核苷酸修饰铝纳米粒疫苗佐剂-传递系统及基于其的SARS-CoV-2亚单位疫苗
AU2021329884A1 (en) * 2020-08-17 2023-02-16 SURGE Therapeutics, Inc. Immune modulation of myeloid derived suppressive cell function for cancer treatment
EP4199961A4 (en) * 2020-08-20 2024-03-13 The Board of Regents of the University of Texas System COMBINATION IMMUNOTHERAPY METHODS FOR THE TREATMENT OF CANCER
WO2022093658A1 (en) * 2020-11-01 2022-05-05 Tianxin Wang In situ vaccine for cancer cell and tumor treatment
IL303350A (en) 2020-12-04 2023-08-01 Macrogenics Inc Preparations containing an antibody against HER2/NEU and their use
CN113181359B (zh) * 2021-04-09 2023-06-20 华南理工大学 一种磁热-免疫联合用药物及其应用
EP4308090A1 (en) 2021-04-26 2024-01-24 The Regents of University of California Drug implants containing enzalutamide and methods of use thereof
BR112023022439A2 (pt) * 2021-04-26 2023-12-26 Celanese Eva Performance Polymers Llc Dispositivo implantável para liberação sustentada de um composto de fármaco macromolecular
WO2022271033A1 (en) * 2021-06-24 2022-12-29 Seljelid, Rolf Combination of an oncolytic virus, an anti-pd-1 inhibitor and an activator of the innate immune system for use in the treatment of prostate cancer
CA3226976A1 (en) * 2021-07-23 2023-01-26 Immunesensor Therapeutics, Inc. Sting agonist combination treatments with cytokines
WO2023096899A1 (en) * 2021-11-24 2023-06-01 Amacathera Hydrogel pharmaceutical compositions
CN114432502B (zh) * 2021-12-31 2023-02-03 中山大学附属第八医院（深圳福田） 一种负载op3-4多肽、抗cxcl9抗体的水凝胶及其制备方法与应用
CN114452442A (zh) * 2022-01-30 2022-05-10 上海松力生物技术有限公司 一种原位诱导子宫壁组织再生的植入物
US20230256056A1 (en) * 2022-02-11 2023-08-17 Insitu Biologics, Inc. Sustained release cancer therapeutics formulations
WO2023195807A1 (ko) * 2022-04-06 2023-10-12 웰마커바이오 주식회사 돌연변이형 ron 저해제 및 항-pd-1 항체를 포함하는 암 치료용 약학 조성물
CN115590947A (zh) * 2022-05-27 2023-01-13 苏州大学（Cn） 联合免疫用药物、温敏凝胶组合物、趋化因子颗粒及其应用
CN115058440B (zh) * 2022-06-08 2023-08-15 郑州轻工业大学 催化合成天然蔗糖酯的工程菌及其构建方法和应用
CN115232306B (zh) * 2022-07-08 2023-11-24 苏州大学 一种氟化修饰的直链聚β-氨基酯及其制备方法与应用

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
US5268376A (en) 1991-09-04 1993-12-07 Minnesota Mining And Manufacturing Company 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines
AU681687B2 (en) 1993-07-15 1997-09-04 Minnesota Mining And Manufacturing Company Imidazo(4,5-c)pyridin-4-amines
ES2290969T3 (es) 1996-10-25 2008-02-16 Minnesota Mining And Manufacturing Company Compuestos modificadores de la respuesta inmune para el tratamiento de enfermedades mediadas por th2 y relacionadas.
US20020164374A1 (en) 1997-10-29 2002-11-07 John Jackson Polymeric systems for drug delivery and uses thereof
UA67760C2 (uk) 1997-12-11 2004-07-15 Міннесота Майнінг Енд Мануфакчурінг Компані Імідазонафтиридин та тетрагідроімідазонафтиридин, фармацевтична композиція, спосіб індукування біосинтезу цитокінів та спосіб лікування вірусної інфекції, проміжні сполуки
US6110929A (en) 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
AU1374601A (en) 1999-11-12 2001-05-30 Angiotech International Ag Compositions and methods for treating disease utilizing a combination of radioactive therapy and cell-cycle inhibitors
US20030157161A1 (en) * 2001-05-01 2003-08-21 Angiotech Pharmaceuticals, Inc. Compositions and methods for treating inflammatory conditions utilizing protein or polysaccharide containing anti-microtubule agents
US20020192280A1 (en) 2001-05-01 2002-12-19 Angiotech Pharmaceuticals, Inc. Compositions and methods for treating inflammatory conditions utilizing protein or polysaccharide containing anti-microtubule agents
MXPA05003183A (es) 2002-09-26 2005-06-08 Angiotech Int Ag Evolturas perivasculares.
WO2005079195A2 (en) 2003-10-03 2005-09-01 3M Innovative Properties Company Pyrazolopyridines and analogs thereof
US7524275B2 (en) 2003-11-14 2009-04-28 Cytyc Corporation Drug eluting brachytherapy methods and apparatus
US20080247987A1 (en) 2005-08-04 2008-10-09 Angiotech International Ag Block Copolymer Compositions and Uses Thereof
KR100741990B1 (ko) 2006-07-10 2007-07-23 삼성전자주식회사 반도체 장치 및 그 제조 방법
US9370558B2 (en) * 2008-02-13 2016-06-21 President And Fellows Of Harvard College Controlled delivery of TLR agonists in structural polymeric devices
WO2010017248A2 (en) 2008-08-04 2010-02-11 University Of Miami Sting (stimulator of interferon genes), a regulator of innate immune responses
WO2011078990A1 (en) * 2009-12-14 2011-06-30 Benaroya Research Institute At Virginia Mason Hydrogels comprising hyaluronan and at least one t cell induction agent
WO2013169864A2 (en) 2012-05-08 2013-11-14 Lycera Corporation TETRAHYDRO[1,8]NAPHTHYRIDINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORƴ AND THE TREATMENT OF DISEASE
IN2014MN02492A (da) 2012-06-08 2015-07-17 Aduro Biotech
AU2013358892B2 (en) 2012-12-13 2018-06-21 Aduro Biotech, Inc. Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use
ES2678194T3 (es) 2012-12-19 2018-08-09 Board Of Regents, The University Of Texas System Determinación farmacéutica de una vía de señalización de dinucleótido cíclico de mamífero
SG10201708821RA (en) 2013-04-29 2017-12-28 Memorial Sloan Kettering Cancer Center Compositions and methods for altering second messenger signaling
WO2014179760A1 (en) 2013-05-03 2014-11-06 The Regents Of The University Of California Cyclic di-nucleotide induction of type i interferon
AP2015008700A0 (en) 2013-05-18 2015-08-31 Univ California Compositions and methods for activating "stimulator of interferon gene"-dependent signalling
EP3027227A4 (en) 2013-07-31 2018-05-23 Memorial Sloan Kettering Cancer Center Sting crystals and modulators
US20150094518A1 (en) 2013-09-27 2015-04-02 The Regents Of The University Of California Modular polymer platform for the treatment of cancer
EP3071209A4 (en) 2013-11-19 2017-08-16 The University of Chicago Use of sting agonist as cancer treatment
MX2016010998A (es) 2014-02-27 2017-03-31 Lycera Corp Terapia celular adoptiva que usa un agonista de receptor huérfano gamma relacionado con receptor de ácido retinoico y métodos terapéuticos relacionados.
US9364545B2 (en) 2014-06-19 2016-06-14 Taipei Medical University Thermosensitive injectable hydrogel for drug delivery
US20170136127A1 (en) 2014-07-01 2017-05-18 Vicus Therapeutics, Llc Hydrogels for treating and ameliorating cancers and potentiating the immune system and methods of making and using them
KR101646643B1 (ko) 2014-08-27 2016-08-11 성균관대학교산학협력단 생체친화성 음이온 고분자 기반 약물 전달용 조성물 및 이의 제조 방법
US20180229623A1 (en) 2014-10-09 2018-08-16 Borgwarner Inc. Control systems for hydraulically actuated transmissions of electric vehicles
CN105983097B (zh) * 2015-01-28 2021-06-08 华中科技大学同济医学院附属协和医院 一种抗肿瘤制剂及其制备方法
CA3012602A1 (en) * 2015-01-30 2016-08-04 President And Fellows Of Harvard College Peritumoral and intratumoral materials for cancer therapy
AU2016304899B2 (en) 2015-08-13 2018-11-08 Merck Sharp & Dohme Llc Cyclic di-nucleotide compounds as sting agonists
AU2016362697B2 (en) 2015-12-03 2018-07-12 Glaxosmithkline Intellectual Property Development Limited Cyclic purine dinucleotides as modulators of STING
BR112018013808A2 (pt) 2016-01-11 2018-12-11 Innate Tumor Immunity, Inc. dinucleotídeos cíclicos para o tratamento de condições associadas à atividade de sting, tal como câncer
WO2017123657A1 (en) 2016-01-11 2017-07-20 Gary Glick Cyclic dinucleotides for treating conditions associated with sting activity such as cancer
US20190060286A1 (en) 2016-02-29 2019-02-28 University Of Florida Research Foundation, Incorpo Chemotherapeutic Methods
DK3506884T3 (da) * 2016-08-30 2021-07-26 Dana Farber Cancer Inst Inc Sammensætninger til indgivelse af medicin og anvendelser af disse

Also Published As

Publication number Publication date
KR20190043162A (ko) 2019-04-25
US20190153098A1 (en) 2019-05-23
CN110121335A (zh) 2019-08-13
BR112019004042A2 (pt) 2019-05-28
EP3922279A1 (en) 2021-12-15
WO2018045058A1 (en) 2018-03-08
US10413612B2 (en) 2019-09-17
US11021539B2 (en) 2021-06-01
US10435469B2 (en) 2019-10-08
KR102497742B1 (ko) 2023-02-10
JP7240311B2 (ja) 2023-03-15
US20190382492A1 (en) 2019-12-19
US20210246211A1 (en) 2021-08-12
US20200031930A1 (en) 2020-01-30
CA3033542A1 (en) 2018-03-08
KR102650076B1 (ko) 2024-03-20
KR20230023060A (ko) 2023-02-16
JP2019530658A (ja) 2019-10-24
AU2023266240A1 (en) 2023-12-07
EP3506884B1 (en) 2021-05-05
AU2017321609B2 (en) 2023-08-17
AU2017321609C1 (en) 2023-11-09
US10836826B2 (en) 2020-11-17
US20190083626A1 (en) 2019-03-21
JP2023078198A (ja) 2023-06-06
EP3506884A1 (en) 2019-07-10
AU2017321609A1 (en) 2019-02-28

Similar Documents

Publication Publication Date Title
DK3506884T3 (da) Sammensætninger til indgivelse af medicin og anvendelser af disse
DK3313817T3 (da) Bicycliske derivater, fremgansmåde til deres fremstilling og farmaceutiske sammensætninger indeholdende disse
DK3463248T3 (da) Anordnnger til anvendelse af lægemiddelanordninger
DK3529248T3 (da) Farmaceutiske sammensætninger
DK3286181T3 (da) Pyrazolforbindelser og fremgangsmåde til fremstilling og anvendelse af forbindelserne
DK3357513T3 (da) Farmaceutisk sammensætning og anvendelse deraf
DK3487505T3 (da) Indgivelse og dosering af diaminophenothiaziner
DK3237045T3 (da) Indretning til indgivelse af lægemidler
DK3393655T3 (da) Fenfluramin-sammensætninger og fremgangsmåder til fremstilling af samme
DK3319948T3 (da) Acesulfam-kaliumsammensætninger og fremgangsmåder til fremstilling af disse
DK3102555T3 (da) Sammensætninger af forbindelser og anvendelser deraf
DK3322695T3 (da) Acesulfam-kalium-sammensætninger og fremgangsmåder til fremstilling af disse
DK3331879T3 (da) Benzazolforbindelser og fremgangsmåder til fremstilling og anvendelse af forbindelserne
DK3532029T3 (da) Flydende farmaceutisk sammensætning
DK3357491T3 (da) Farmaceutisk sammensætning til afgivelse af et anionisk medikament
DK2924093T3 (da) Multicarboxylat-sammensætninger og fremgangsmåde til fremstilling af disse
DK3412660T3 (da) Sulfonamidderivat og farmaceutisk sammensætning indeholdende samme
DK3255042T3 (da) Heterocyklisk forbindelse og farmaceutisk sammensætning omfattende samme
DK3380525T3 (da) Farmaceutiske formuleringer og fremgangsmåder til anvendelse deraf
DK3821905T3 (da) Insulin indeholdende farmaceutiske sammensætninger
DK3319949T3 (da) Acesulfam-kalium-sammensætninger og fremgangsmåder til fremstilling af disse
DK2956149T3 (da) Farmaceutiske sammensætninger til behandling af helicobacter pylori
DK3468604T3 (da) Farmaceutiske kombinationer til behandling af cancer
DK3200748T3 (da) Sammensætninger og fremgangsmåder til behandling og profylakse af infektioner på operationssted
DK3280474T3 (da) Indretning til levering af nasalt medikament